Cancer responding poorly to chemotherapy
Potential benefit studied: Improved treatment response, progression or survival when added to chemotherapy
Supporting researchThis is cancer research, not a product treatment claim. These studies do not establish that Longevity or Mobility prevents, treats or cures cancer.
A randomized human trial reported a survival signal when curcumin was added to FOLFOX chemotherapy for colorectal cancer.
A randomized colorectal-cancer trial analysed 27 patients receiving FOLFOX chemotherapy, with or without 2 g daily curcumin.
These trials used supervised oncology regimens and specific preparations, not Longevity or Mobility. The results do not establish retail-product efficacy. Anyone receiving chemotherapy should discuss supplement use with their oncology team before starting.
The doses above describe research, not personal dosing instructions. Ingredient studies do not diagnose symptoms or establish medical suitability. Discuss medicines, existing conditions and treatment decisions with an appropriate healthcare professional.